GO:0004862 cAMP-dependent protein kinase inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004862 describes a molecular function: the ability of a protein to bind to and inhibit cAMP-dependent protein kinase (PKA).
• PKA inhibition is a key regulatory node in cAMP signaling, affecting processes from synaptic plasticity to platelet activation [1,4].
• Small-molecule inhibitors such as H-89 are widely used to probe PKA function, but they can have off-target effects, including interference with luciferase reporters.
• Endogenous inhibitors like PKI (protein kinase inhibitor) are critical for terminating PKA signaling and are conserved across tissues.
• Dysregulation of PKA inhibition has been implicated in neurological and cardiovascular conditions, and PKA inhibitors show antidepressant-like effects in animal models.
• Studying GO:0004862 requires careful experimental design, often combining genetic knockout, point mutations, and pharmacological tools [6,7].
Description
The Gene Ontology (GO) term GO:0004862, cAMP-dependent protein kinase inhibitor activity, defines a molecular function in which a protein binds to and reduces the enzymatic activity of cAMP-dependent protein kinase (PKA). PKA is a central effector of cAMP signaling, phosphorylating a wide array of substrates to control metabolism, gene expression, and cell shape. Because unrestrained PKA activity can be detrimental, cells express endogenous inhibitors that act as brakes on the pathway. Understanding this inhibitory function is therefore essential for dissecting how cAMP signals are shaped in time and space. The importance of PKA inhibition extends to synaptic function, where PKA activity regulates the synaptic targeting of NMDA receptors, a process critical for learning and memory. In the vasculature, PKA activity influences endothelial cell cytoskeleton rearrangement, and its inhibition can alter barrier function. Platelet procoagulant activity is also modulated by PKA, highlighting the role of this kinase in thrombosis. Moreover, PKA inhibitors are used experimentally to probe these pathways, although careful controls are needed because some inhibitors, like H-89, can affect other reporters. This article synthesizes authoritative GO annotations and verified literature to provide a research-grade overview of GO:0004862, covering its mechanism, key genes, disease relevance, and methods for study.
cAMP-dependent protein kinase inhibitor activity At A Glance
| GO ID | GO:0004862 |
|---|---|
| GO term | cAMP-dependent protein kinase inhibitor activity |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Binds to and inhibits cAMP-dependent protein kinase (PKA) |
| Related kinase | cAMP-dependent protein kinase (PKA) |
| Endogenous examples | Protein kinase inhibitor (PKI) peptides |
| Common pharmacological tools | H-89, KT5720, and others |
| Pathological relevance | Neurological and cardiovascular disorders |
What Is GO:0004862?
According to the Gene Ontology, GO:0004862 (cAMP-dependent protein kinase inhibitor activity) is a molecular function defined as binding to and stopping, preventing, or reducing the activity of a cAMP-dependent protein kinase. In other words, it is the function of a protein that directly interacts with PKA and dampens its ability to phosphorylate substrates. This activity is distinct from other types of kinase inhibition because it specifically targets PKA, the primary effector of cAMP signaling.
Why Is cAMP-dependent protein kinase inhibitor activity Important in Cell Biology?
GO:0004862 is important because it represents a fundamental control point in cAMP signaling, a pathway that regulates numerous physiological processes. By inhibiting PKA, cells can fine-tune the duration and intensity of cAMP signals, which is crucial for proper cellular responses. Dysregulation of this inhibitory function has been linked to disease states, including depression-like behaviors in animal models and altered platelet function. Moreover, understanding PKA inhibition is essential for interpreting experiments that use pharmacological inhibitors, as off-target effects can confound results.
• Regulates synaptic plasticity by controlling PKA-dependent NMDA receptor trafficking.
• Modulates endothelial cell cytoskeleton rearrangement and barrier function.
• Influences platelet procoagulant activity and thrombosis.
• Mediates antidepressant-like behavioral and neurological effects in rats.
• Provides a target for drug design in cancer and other diseases.
• Is essential for terminating cAMP signals to prevent aberrant PKA activity.
• Can be studied using genetic knockouts and point mutations to dissect specific residues.
• Pharmacological inhibitors like H-89 are widely used but require careful controls due to off-target effects.
Molecular Mechanism of cAMP-dependent protein kinase inhibitor activity
Recognition and Binding to PKA
In simple terms: The inhibitor protein finds and attaches to PKA.
The inhibitor binds directly to the catalytic subunit of PKA, often through a pseudosubstrate motif that mimics PKA substrates but lacks a phosphorylatable residue. This binding is highly specific and prevents PKA from interacting with its true substrates.
Inhibition of Catalytic Activity
In simple terms: Once bound, the inhibitor stops PKA from working.
Binding of the inhibitor blocks the active site of PKA, preventing ATP and substrate access, thereby reducing phosphorylation of downstream targets. This inhibition can be competitive or non-competitive depending on the inhibitor.
Regulation by Cellular Signals
In simple terms: The inhibitor itself can be controlled by other signals.
The activity of endogenous inhibitors like PKI can be regulated by phosphorylation, degradation, or changes in expression levels, allowing dynamic control of PKA output. For example, nerve growth factor stimulation can render B-Raf refractory to PKA inhibition, indirectly affecting the pathway.
Pharmacological Inhibition
In simple terms: Drugs can also block PKA, but they may have side effects.
Small molecules such as H-89 inhibit PKA by competing with ATP, but they can also affect other kinases and even luciferase reporters, necessitating careful interpretation of results. These inhibitors are valuable for acute experiments but should be validated with genetic approaches.
Key Genes Involved in GO:0004862 cAMP-dependent protein kinase inhibitor activity
The following genes and proteins are directly or indirectly involved in cAMP-dependent protein kinase inhibitor activity, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRKACA | Catalytic subunit of PKA; target of inhibition | Mutations cause Cushing's syndrome; target for inhibitors |
| PRKACB | Catalytic subunit of PKA; target of inhibition | Isoform-specific functions in neurons |
| PRKAR1A | Regulatory subunit of PKA; modulates PKA activity | Mutations in Carney complex |
| PKIA | Endogenous PKA inhibitor (PKIα) | Regulates PKA in muscle and brain |
| PKIB | Endogenous PKA inhibitor (PKIβ) | Testis-specific inhibitor |
| PKIG | Endogenous PKA inhibitor (PKIγ) | Widely expressed inhibitor |
| H-89 | Pharmacological PKA inhibitor | Commonly used but off-target effects on luciferase |
| B-Raf | Kinase in MAPK pathway; affected by PKA | NGF-stimulated B-Raf is refractory to PKA inhibition |
| NMDA receptor | Ion channel; regulated by PKA | PKA inhibition alters synaptic targeting |
| GRIN1 | NMDA receptor subunit | Phosphorylated by PKA; affects trafficking |
| GRIN2A | NMDA receptor subunit | PKA-dependent synaptic localization |
| GRIN2B | NMDA receptor subunit | PKA-dependent synaptic localization |
| VASP | Actin regulatory protein; PKA substrate | PKA inhibition affects cytoskeleton |
| Rap1 | Small GTPase; modulated by PKA | PKA inhibition alters platelet adhesion |
| Renilla luciferase | Reporter enzyme; affected by H-89 | H-89 attenuates bioluminescence |
How Is cAMP-dependent protein kinase inhibitor activity Regulated?
The activity of cAMP-dependent protein kinase inhibitors is regulated at multiple levels. Endogenous inhibitors such as PKI are subject to transcriptional control and post-translational modifications that alter their affinity for PKA. Additionally, the subcellular localization of inhibitors can be dynamically regulated, allowing compartmentalized PKA inhibition. Pharmacological inhibitors are not subject to cellular regulation but their effects can be modulated by off-target interactions, as seen with H-89 and Renilla luciferase.
cAMP-dependent protein kinase inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRKACA | Cushing's syndrome, cancer | Knock-in of activating mutations in cell lines |
| PKIA | Depression-like behaviors | Knockout mice for behavioral studies |
| GRIN2B | Schizophrenia, addiction | Point mutations in NMDA receptor subunits |
| VASP | Cardiovascular disease | Overexpression of phospho-mimetic mutants |
| Rap1 | Thrombosis | Knockout platelets for aggregation assays |
Neurological and Psychiatric Disorders
Dysregulation of PKA signaling has been implicated in depression and other mood disorders. An inhibitor of cAMP-dependent protein kinase induced antidepressant-like behavioral and neurological effects in rats, suggesting that modulating PKA inhibition could be a therapeutic strategy. Additionally, PKA activity is critical for synaptic plasticity, and its inhibition affects NMDA receptor trafficking, which is relevant to learning and memory disorders.
Cardiovascular and Thrombotic Disorders
PKA plays a key role in platelet function and endothelial barrier regulation. Inhibition of PKA affects platelet procoagulant activity, linking this function to thrombosis and hemostasis. In endothelial cells, PKA activity influences cytoskeleton rearrangement, and its inhibition can alter vascular permeability.
Cancer and Cell Proliferation
PKA signaling is frequently dysregulated in cancer, and inhibitors of PKA are being explored as anticancer agents. The development of selective PKA inhibitors for drug design is an active area, with the goal of targeting specific PKA isoforms or subcellular pools.
From cAMP-dependent protein kinase inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PKI increase PKA activity? | PKIA knockout cell line |
| How does a point mutation in PKA affect inhibitor binding? | Knock-in of mutant PRKACA |
| Can a tagged inhibitor be used for localization studies? | Knock-in of GFP-PKIA |
| What is the effect of PKA inhibition on gene expression? | Overexpression of PKI followed by RNA-seq |
| Which genes are essential for PKA inhibitor function? | CRISPR library screening |
| Does pharmacological inhibition mimic genetic inhibition? | H-89 treatment vs. PKI knockout |
How to Study the cAMP-dependent protein kinase inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Phosphorylation of PKA substrates | Assessing PKA activity in cells |
| Kinase assay | Enzymatic activity of PKA | Testing inhibitor potency in vitro |
| CRISPR knockout | Loss of inhibitor gene function | Validating endogenous inhibitor roles |
| RNA-seq | Transcriptional changes upon PKA inhibition | Identifying downstream targets |
| FRET biosensors | Real-time PKA activity | Live-cell imaging of signaling dynamics |
| Mass spectrometry | Post-translational modifications of PKA | Detecting glutathionylation |
| Luciferase reporter assay | Effect of inhibitors on reporter enzymes | Controlling for off-target effects |
Genetic Approaches
CRISPR-Cas9 knockout of endogenous PKA inhibitor genes (e.g., PKIA) can reveal their contribution to PKA signaling. Point mutations can be introduced to disrupt specific interaction interfaces, and knock-in of tagged versions allows for localization and interaction studies.
Pharmacological Inhibition
Small-molecule inhibitors like H-89 are widely used to acutely inhibit PKA, but their specificity must be validated. For example, H-89 attenuates Renilla luciferase bioluminescence, which can confound reporter assays.
Biochemical Assays
In vitro kinase assays using purified PKA and substrates can measure inhibitor potency. Glutathionylation of PKA can regulate its activity, and such modifications can be studied using mass spectrometry.
Imaging and Live-Cell Studies
Fluorescent reporters of PKA activity (e.g., AKAR) can visualize real-time inhibition in live cells. These tools help dissect spatial and temporal dynamics of PKA inhibition.
How CRISPR Can Be Used to Study GO:0004862 cAMP-dependent protein kinase inhibitor activity
Knockout
CRISPR knockout of PKA inhibitor genes such as PKIA can be used to assess the consequences of losing endogenous inhibition. This approach can reveal changes in PKA substrate phosphorylation and downstream phenotypes.
Point Mutation
Introducing point mutations into the inhibitor gene can disrupt its binding to PKA without affecting its expression. This helps map the interaction interface and understand specificity.
Knock-in
Knock-in of tagged versions (e.g., GFP or HA) of PKA inhibitors allows for localization and interaction studies using imaging and immunoprecipitation.
Overexpression
Overexpression of PKA inhibitors can be achieved by CRISPR activation or by lentiviral delivery. This can suppress PKA signaling and mimic pharmacological inhibition, but may also cause non-physiological effects.
How EDITGENE Supports cAMP-dependent protein kinase inhibitor activity Research
Researchers studying cAMP-dependent protein kinase inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in PKA regulation or disease. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations, from gene knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for cAMP-dependent protein kinase inhibitor activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PRKAG2 Knockout HEK293 Cell Line | EDJ-KQ1451 | Human | 51422 | Details Get a Quote |
| PPP1R1B Knockout HEK293 Cell Line | EDJ-KQ1806 | Human | 84152 | Details Get a Quote |
| PRKAR1B Knockout HEK293 Cell Line | EDJ-KQ3331 | Human | 5575 | Details Get a Quote |
| PRKAR2A Knockout HEK293 Cell Line | EDJ-KQ3483 | Human | 5576 | Details Get a Quote |
| PKIB Knockout HEK293 Cell Line | EDJ-KQ5533 | Human | 5570 | Details Get a Quote |
| PRKAR2B Knockout HEK293 Cell Line | EDJ-KQ5536 | Human | 5577 | Details Get a Quote |
| PJA2 Knockout HEK293 Cell Line | EDJ-KQ6792 | Human | 9867 | Details Get a Quote |
| PKIG Knockout HEK293 Cell Line | EDJ-KQ7300 | Human | 11142 | Details Get a Quote |
| PRKAG2 Knockout A-549 Cell Line | EDJ-KQ21004 | Human | 51422 | Details Get a Quote |
| PRKAG2 Knockout HCT 116 Cell Line | EDJ-KQ21005 | Human | 51422 | Details Get a Quote |
| PRKAG2 Knockout HeLa Cell Line | EDJ-KQ21006 | Human | 51422 | Details Get a Quote |
| PRKAR1B Knockout A-549 Cell Line | EDJ-KQ24955 | Human | 5575 | Details Get a Quote |
| PRKAR1B Knockout HCT 116 Cell Line | EDJ-KQ24956 | Human | 5575 | Details Get a Quote |
| PRKAR1B Knockout HeLa Cell Line | EDJ-KQ24957 | Human | 5575 | Details Get a Quote |
| PKIG Knockout HeLa Cell Line | EDJ-KQ30972 | Human | 11142 | Details Get a Quote |
- 1
- 2
- Next Page »
Frequently Asked Questions About cAMP-dependent protein kinase inhibitor activity
What is cAMP-dependent protein kinase inhibitor activity?
It is a molecular function defined by GO:0004862, where a protein binds to and inhibits the activity of cAMP-dependent protein kinase (PKA).
What genes are involved in cAMP-dependent protein kinase inhibitor activity?
Key genes include PKIA, PKIB, and PKIG, which encode endogenous PKA inhibitor proteins, as well as the PKA subunits PRKACA and PRKACB.
How is cAMP-dependent protein kinase inhibitor activity regulated?
It is regulated by expression levels, post-translational modifications, and subcellular localization of inhibitor proteins.
What diseases are associated with cAMP-dependent protein kinase inhibitor activity?
Dysregulation has been linked to depression-like behaviors, cardiovascular disorders, and cancer [5,4,6].
What are common inhibitors of PKA?
H-89 is a widely used pharmacological inhibitor, but it can have off-target effects, such as inhibiting luciferase.
How can I study cAMP-dependent protein kinase inhibitor activity?
You can use CRISPR knockout, point mutations, pharmacological inhibitors, and biochemical assays [6,8].
What is the role of PKA inhibition in synaptic plasticity?
PKA inhibition affects NMDA receptor trafficking, which is important for synaptic plasticity and memory.
Does PKA inhibition affect platelet function?
Yes, PKA inhibition modulates platelet procoagulant activity, influencing thrombosis.
Can PKA inhibitors be used as antidepressants?
In animal models, PKA inhibitors induced antidepressant-like effects, suggesting a potential therapeutic avenue.
What are the challenges in studying PKA inhibitors?
Off-target effects of pharmacological inhibitors and redundancy among endogenous inhibitors can complicate interpretation [8,6].
Conclusion
GO:0004862, cAMP-dependent protein kinase inhibitor activity, is a critical molecular function that regulates PKA signaling, impacting diverse physiological and pathological processes. From synaptic plasticity to platelet function, the precise control of PKA activity by inhibitors is essential. Understanding this function through genetic and pharmacological approaches can reveal new therapeutic targets. EDITGENE's CRISPR services provide powerful tools to dissect the roles of PKA inhibitors in health and disease.
References
- 1. Crump FT et al.. 2001. cAMP-dependent protein kinase mediates activity-regulated synaptic targeting of NMDA receptors.. J Neurosci 21(14):5079-88 PMID: 11438583
- 2. Liu F et al.. 2001. Role of cAMP-dependent protein kinase A activity in endothelial cell cytoskeleton rearrangement.. Am J Physiol Lung Cell Mol Physiol 280(6):L1309-17 PMID: 11350812
- 3. Humphries KM et al.. 2002. Regulation of cAMP-dependent protein kinase activity by glutathionylation.. J Biol Chem 277(45):43505-11 PMID: 12189155
- 4. Yan R et al.. 2009. Role of cAMP-dependent protein kinase in the regulation of platelet procoagulant activity.. Arch Biochem Biophys 485(1):41-8 PMID: 19268649
- 5. Liebenberg N et al.. 2011. An inhibitor of cAMP-dependent protein kinase induces behavioural and neurological antidepressant-like effects in rats.. Neurosci Lett 498(2):158-61 PMID: 21596096
- 6. Taylor SS et al.. 2008. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design.. Biochim Biophys Acta 1784(1):16-26 PMID: 17996741
- 7. MacNicol MC et al.. 1999. Nerve growth factor-stimulated B-Raf catalytic activity is refractory to inhibition by cAMP-dependent protein kinase.. J Biol Chem 274(19):13193-7 PMID: 10224075
- 8. Herbst KJ et al.. 2009. The cAMP-dependent protein kinase inhibitor H-89 attenuates the bioluminescence signal produced by Renilla Luciferase.. PLoS One 4(5):e5642 PMID: 19461967
